Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Gastrointestinal tumours, non-colorectal

1091 - A phase I and randomized phase II trial to evaluate the efficacy and safety of nab-paclitaxel (nab-P) in combination with gemcitabine (G) for the treatment of patients with ECOG 2 advanced pancreatic cancer (PDAC).

Date

11 Sep 2017

Session

Gastrointestinal tumours, non-colorectal

Presenters

Manuel Hidalgo

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

M. Hidalgo1, R. Pazo-Cid2, C. Guillen-Ponce3, R. López4, R. Vera5, M. Reboredo6, A. Muñoz7, E. Martinez de Castro8, R. Díaz Beveridge9, A. La Casta10, J.I. Martin-Valades11, A. Cubillo12, J. Martínez-Galán13, I. Ales14, J. Sastre15, T. Macarulla Mercade16

Author affiliations

  • 1 Medical Oncology Department, Beth Israel Deaconess Medical Center,, MA 02215 - Boston/ES
  • 2 Medical Oncology Department, Miguel Servet University Hospital, Zaragoza/ES
  • 3 Medical Oncology Department, Hospital Universitario Ramon y Cajal, 28031 - Madrid/ES
  • 4 Medical Oncology Department, HOSPITAL CLINICO DE SANTIAGO, Santiago de Compostela/ES
  • 5 Medical Oncology, Hospital de Navarra, 31008 - Pamplona/ES
  • 6 Medical Oncology Department, Hospital Universitario a Coruna - a Coruna, 15006 - A Coruna/ES
  • 7 Medical Oncology Department, Hospital General Universitario Gregorio Marañon, Madrid/ES
  • 8 Medical Oncology, Hospital Universitario Marques de Valdecilla, 39008 - Santander/ES
  • 9 Medical Oncology, Hospital Universitari i Politècnic La Fe, 46026 - Valencia/ES
  • 10 Medical Oncology Department, Hospital Universitario Donostia, Donostia/ES
  • 11 Medical Oncology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid/ES
  • 12 Medical Oncology Department, Hospital Madrid Norte San Chinarro Centro Integral Oncologico Clara Campal, 28050 - Madrid/ES
  • 13 Medical Oncology Department, Hospital Universitario Virgen de las Nieves, Granada/ES
  • 14 Medical Oncology Department, Hospital Universitario Carlos Haya, Málaga/ES
  • 15 Medical Oncology Department, Hospital Clinico Universitario San Carlos, 28040 - Madrid/ES
  • 16 Medical Oncology Department, Vall d`Hebron Institute of Oncology (VHIO)-Cellex Center, 08035 - Barcelona/ES
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1091

Background

Nab-P+G significantly improved overall survival versus G in Patients (P) with Karnofsky index ≥70% metastatic PDAC (Von Hoff et al, 2013). The aim of this study was to select a tolerable dose -schedule of nab-P+G (Ph I), and to evaluate the efficacy of the selected regimen (Ph II) in patients with previously untreated ECOG-2 advanced PDAC.

Methods

In the phase1 portion of the study patients were randomized to one of 4 treatment regimens including G 1000 mg/m2 and nab-P 150 mg/m2 (arm B) or 125 mg/m2 (arm D) days 1 and 15 every 28 days or same dose of G and nab-P 100 mg/m2 (arm C) or 125 mg/m2 (arm E) days 1, 8, and 15 every 28 days. The two safest regimens determined by analyzing hematological and non-hematological grade 3-4 toxicity, 30 and 60 days mortality, treatment discontinuation due to toxicity and dose intensity were selected for evaluation in the phase 2 portion of the study with 6 months overall survival (OS) as the primary endpoint.

Results

Regimens arm C and arm E (days 1, 8, 15 every 28 days schedule) were selected for the phase 2 portion of the study. A total of 221 patients (111 in arm C/110 in arm E) were enrolled. Median age was 71/68 y, 51/55% were male and 91/83% had metastatic disease (liver 63/62%). Most frequent grade 3-4 toxicity per arm were anemia (12/7%), neutropenia (32/30%), thrombocytopenia (7/11%), febrile neutropenia (3/4%), asthenia (14/16%) and neurotoxicity (11/16%). There were no significant differences in 6 months OS 63/69%, response rate (RR) 24/28% and median progression free survival (PFS) 5.7/6.7 months respectively in each arm.

Conclusions

Nab-P in combination with G, both at 100 and 125 mg/m2 dose administered on a standard schedule of days 1, 8 and 15 is well tolerated and results in acceptable OS, RR and PFS in this fragile patient population.

Clinical trial identification

NCT02382263 EudraCT: 2012-003605-97

Legal entity responsible for the study

PH Research

Funding

Celgene

Disclosure

M. Hidalgo: Honoraria: Celgene. Consulting or advisory role: Celgene. Research funding: Celgene. Travel, accomodations: Celgene. R. Pazo-Cid: Consulting or advisory role: Celgene, Baxalta. A. Muñoz: Consulting or advisory role: Celgene. J. Sastre: Consulting or advisory role: Amgen, Sanofi, Bayer, Boheringer. Travel accomodations: Merck. Researcha funding: Amgen, Merck. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings